Cargando…
A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML
HOXA9 and MEIS1 are frequently upregulated in acute myeloid leukemia (AML), including those with MLL-rearrangement. Because of their pivotal role in hemostasis, HOXA9 and MEIS1 appear non-druggable. We, thus, interrogated gene expression data of pre-leukemic (overexpressing Hoxa9) and leukemogenic (...
Autores principales: | Hassan, Jacob Jalil, Lieske, Anna, Dörpmund, Nicole, Klatt, Denise, Hoffmann, Dirk, Kleppa, Marc-Jens, Kustikova, Olga S., Stahlhut, Maike, Schwarzer, Adrian, Schambach, Axel, Maetzig, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431012/ https://www.ncbi.nlm.nih.gov/pubmed/34502319 http://dx.doi.org/10.3390/ijms22179411 |
Ejemplares similares
-
A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML
por: Lieske, Anna, et al.
Publicado: (2022) -
Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory
por: Stahlhut, Maike, et al.
Publicado: (2021) -
Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding
por: Maetzig, Tobias, et al.
Publicado: (2022) -
Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment
por: Klatt, Denise, et al.
Publicado: (2020) -
HOXA9/MEIS1 targets in leukemia: reinforced signaling networks and therapeutic opportunities
por: Zhou, Xinyue, et al.
Publicado: (2022)